Delayed access to treatments for rare diseases: Who's to blame?

Respirology

Volumn 20, Issue 3, 2015, Pages 361-369

  Feltmate, Karen ^a   Janiszewski, Peter M ^b   Gingerich, Sheena ^b   Cloutier, Michael ^a  

^a InterMune Canada Inc ^*  (Canada)

^b SCRIPT   (Canada)

Author keywords

market access; orphan drug; rare disease; regulatory approval; reimbursement

Indexed keywords

NEW DRUG; ORPHAN DRUG;

AUSTRALIA; AUTHORITY; CANADA; DRUG APPROVAL; DRUG MARKETING; EUROPE; FINANCIAL MANAGEMENT; FUNDING; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; JAPAN; LAW; NEW ZEALAND; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SINGAPORE; SOUTH KOREA; TAIWAN; UNITED STATES; DRUG MANUFACTURE; ECONOMICS; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; RARE DISEASES; RESPIRATORY TRACT DISEASES;

DRUG APPROVAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES; RESPIRATORY TRACT DISEASES;

EID: 84924596125     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12498     Document Type: Review

References (59)

1. National Institutes of Health. The Genetic and Rare Diseases Information Center (GARD) Fact Sheet, 2010. [Accessed 5 Nov 2014.] Available from URL: http://report.nih.gov/nihfactsheets/Pdfs/TheGeneticAndRareDiseasesInformationCenter%28NHGRI%29.pdf.
2. Azie N, Vincent J,. Rare diseases: the bane of modern society and the quest for cures. Clin. Pharmacol. Ther. 2012; 92: 135-139.
3. Dunoyer M,. Accelerating access to treatments for rare diseases. Nat. Rev. Drug Discov. 2011; 10: 475-476.
4. Food and Drug Administration. Orphan Drug Act, 2013. [Accessed 5 Nov 2014.] Available from URL: http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/orphandrugact/default.htm.
5. Cote T, Kelkar A, Xu K, Braun MM, Phillips MI,. Orphan products: an emerging trend in drug approvals. Nat. Rev. Drug Discov. 2010; 9: 84.
6. Melnikova I,. Rare diseases and orphan drugs. Nat. Rev. Drug Discov. 2012; 11: 267-268.
7. Vancheri C, Failla M, Crimi N, Raghu G,. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur. Respir. J. 2010; 35: 496-504.
8. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al., ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
9. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, du Bois RM,. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19: 740-747.
10. Tas F,. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J. Oncol. 2012; 2012: 647684.
11. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N,. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 2012; 10: 85.
12. ICH. Open consultation on ICH Guidelines. [Accessed 14 Nov 2014.] Available at: http://www.ich.org/products/open-consultation.html
13. European Medicines Agency. Human Medicines: Regulatory Information. [Accessed 12 Nov 2014.] Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/landing/human-medicines-regulatory.jsp&mid=
14. U.S. Department of Health and Human Resources, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry Expedited Programs for Serious Conditions-Drugs and Biologics, 2014. [Accessed 9 Nov 2014.] Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf
15. Food and Drug Administration. Expanded Access to Investigational Drugs for Treatment Use, 2009. [Accessed 13 Nov 2014.] Available at: http://www.gpo.gov/fdsys/pkg/FR-2009-08-13/pdf/E9-19005.pdf
16. Health Canada. Priority of Drug Submissions (Therapeutic Products). Drugs and Health Products, Health Canada. [Accessed 10 Nov 2014.] Available at: http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/pdf/prodpharma/prfs-tpfd-eng.pdf
17. Health Canada. Guidance for Industry-Priority Review of Drug Submissions, 2009. [Accessed 14 Nov 2014.] Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/priorit/priordr-eng.php#a1.5
18. Rawson NSB,. Challenging alarmism about drug safety in Canada with facts: an evidence-based critique of Lexchin. Canadian Health Policy, 2014.
19. Health Canada. Guidance Document. Notice of Compliance with conditions (NOC/c), 2011. [Accessed 10 Nov 2014.] Available at: http://www.hc-sc.gc.ca/dhp-mps/alt-formats/pdf/prodpharma/applic-demande/guide-ld/compli-conform/noccg-accd-eng.pdf
20. Health Canada. Notice of Compliance with conditions (NOC/c), 2014. [Accessed 5 Nov 2014.] Available from URL: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/index-eng.php.
21. Health Canada. Special Access Programme-Drugs. [Accessed 12 Nov 2014.] Available at: http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/pdf/acces/sapfs-pasfd-2002-eng.pdf
22. Japan Pharmaceutical Manufacturers Association. Japan Pharmaceutical Manufacturers Association (JPMA). Pharmaceutical Regulations in Japan, 2014. [Accessed 19 Oct 14.] Available from URL: http://www.jpma.or.jp/english/parj/pdf/2014.pdf.
23. Gross A,. Orphan drugs in Asia. Pacific Bridge Medical, 1 October 2006.
24. Pharmaceuticals and Medical Devices Agency. Profile of Services: 2013-2014, 2014. [Accessed 11 Sep 2014.] Available from URL: http://www.pmda.go.jp/english/about/pdf/profile-of-services.pdf.
25. Orphanet. Orphan Drugs in Japan, 2014. [Accessed 19 Oct 2014.] Available from URL: http://www.orpha.net/consor/cgi-bin/Education-AboutOrphanDrugs.php?lng=EN&stapage=ST-EDUCATION-EDUCATION-ABOUTORPHANDRUGS-JAP.
26. Asia Partnership Conference of Pharmaceutical Associations (APAC). Identification and Clarification of the Differences in Regulatory Requirements between Asian Economies, 2014. [Accessed 19 Oct 2014.] Available from URL: http://www.jpma.or.jp/english/apac/pdf/140624-06.pdf.
27. Bujar M, McAuslane N,. New Drug Approvals in ICH Countries 2004-2013. Center for Innovation in Regulatory Science, 2014. [Accessed 10 Nov 2014.] Available from URL: http://www.cirsci.org/sites/default/files/CIRS-R&D-Briefing-54-%20ICH-approval-times-2004-2013-22apr2014.pdf.
28. Holloway P, Pawlukowski D,. Fast tracking procedures and orphan drug programs in the USA, EU and Australia. Allens: Biotech News 01 Apr, 2003. [Accessed Sep 2014.] Available from URL: http://www.allens.com.au/pubs/bt/1apr03/bio02.htm.
29. Australian Government. Department of Health. Therapeutic Goods Administration. Prescription medicines registration process, 2014. [Accessed 15 Nov 2014.] Available at: https://www.tga.gov.au/prescription-medicines-registration-process.
30. Therapeutic Goods Administration. Access to unapproved therapeutic goods: Personal importation, 2004. [Accessed 14 Sep 2014.] Available from URL: https://www.tga.gov.au/sites/default/files/access-personal-import-guidelines.pdf.
31. Medsafe. Evaluation policy for priority and abbreviated assessments, 2014. [Accessed 14 Oct 2014.] Available from URL: http://www.medsafe.govt.nz/regulatory/Guideline/PriorityAndAbbreviatedAssessments.asp.
32. Melanoma Foundation of New Zealand. How do new medicines become available in New Zealand? [Accessed 14 Nov 2014.] Available at: http://www.melanoma.org.nz/About-Melanoma/Diagnosis-and-Treatment/New-Treatments/New-Medicines-in-NZ/
33. Medsafe. Outcome of consultation on the proposed revision of the abbreviated process policy, 2014. [Accesseed 22 Sep 2014.] Available from URL: http://www.medsafe.govt.nz/consultations/ProposedRevisionOfAbbreviatedProcessPolicyOUTCOME.asp.
34. Medsafe. Medsafe's performance in the evaluation of new and changed medicines during 2013, 2014. [Accesseed 22 Sep 2014.] Available from URL: http://www.medsafe.govt.nz/regulatory/Performance2013.asp.
35. Health Sciences Authority. Guidance on medicinal product registration in Singapore, 2011. [Accessed 20 Oct 2014.] Available from URL: http://www.hsa.gov.sg/content/dam/HSA/HPRG/Western-Medicine/Overview-Framework-Policies/Guidelines-on-Drug-Registration/Guidance%20on%20Medicinal%20Product%20Registration%20in%20Singapore%202011%20(Main%20Guidance%20Document%20Only).pdf.
36. Song P, Gao J, Inagaki Y, Kokudo N, Tang W,. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. Intractable Rare Dis. Res. 2012; 1: 3-9.
37. Orphan drugs benefit from fast-track approval-but are they getting to patients? The Pharma Letter. 11 Jul, 2014. [Accessed 20 Sep 2014.] Available from URL: http://www.thepharmaletter.com/article/orphan-drugs-benefit-from-fast-track-approval-but-are-they-getting-to-patients.
38. Wang T, McAuslane N,. R&D Briefing 53: Availability of new medicines. Centre for Innovation in Regulatory Science, 2014.
39. EUnetHTA. Website, 2014. [Accessed 10 Nov 2014.] Available from URL: http://www.eunethta.eu/.
40. Sullivan SD, Watkins J, Sweet B, Ramsey SD,. Health technology assessment in health-care decisions in the United States. Value Health 2009; 12 (Suppl. 2): S39-44.
41. Canadian Health Policy Institute (CHPI). Comparing Access to New Drugs in Canada's Federal and Provincial Public Drug Plans. Annual Series: How Good Is Your Drug Insurance? Canadian Health Policy, 2014.
42. CADTH. About the Common Drug Review. [Accessed 10 Nov 2014.] Available at: http://www.cadth.ca/en/products/cdr/cdr-overview
43. Intermune. Intermune internal document, 2013.
44. The Exceptional Access Program (EAP). Ontario Ministry of Health and Long-term Care, 2014. [Accessed 14 Nov 2014.] Available from URL: http://www.health.gov.on.ca/en/public/programs/drugs/programs/odb/opdp-eap.aspx.
45. Commonwealth of Australia. Independent review of the impact of Phamaceutical Benefits Scheme (PBS) cost recovery: November 2011, 2012.
46. Australian DoH. Role of the Pharmaceutical Benefits Advisory Committee. PBAC Guidelines, v. 4.4. [Accessed 10 Nov 2014.] Available at: http://www.pbac.pbs.gov.au/information/role-of-pbac.html
47. Pearce A, van Gool K, Haywood P, Haas M,. Delays in access to affordable medicines: putting policy into perspective. Aust. Health Rev. 2012; 36: 412-418.
48. Chalkidou K, Lopert R, Gerber A,. Paying for 'End-of-Life' Drugs in Australia, Germany, and the United Kingdom: Balancing Policy, Pragmatism, and Societal Values. Issues in International Health Policy, 2012.
49. Taylor L,. Australians 'denied new drugs because of too-difficult PBS listing'. PharmaTimes Digital, 28 May, 2013.
50. Australian DoH. Other relevant factors. PBAC Guidelines, v. 4.4. [Accessed 10 Nov 2014.] Available at: http://www.pbac.pbs.gov.au/section-f/f3-other-relevant-factors.html
51. Australian DoH. Cost Recovery, Fees and charges-Frequently Asked Questions. Pharmaceutical Benefits Scheme, 2012.
52. Taskforce MAOI. Access to cancer medicines in Australia. Deloitte Access Economics, 2013.
53. Australian DoH. Framework for the introduction of parallel TGA and PBAC processes. Pharmaceutical Benefits Scheme, 2011.
54. Government congratulated on new Cabinet threshold, 2013. Medicines Australia. [Accessed 14 Nov 2014.] Available at: http://medicinesaustralia.com.au/2013/10/30/government-congratulated-on-new-cabinet-threshold/
55. Taylor L,. Australia scraps drug price watchdog. PharmaTimes Digital, 2014. [Accessed 09 Nov 2014.] Available at: http://www.pharmatimes.com/article/14-03-10/Australia-scraps-drug-price-watchdog.aspx.
56. Australian DoH. Pharmaceutical Benefits Pricing Authority Policies, Procedures and Methods. Pharmaceutical Benefits Scheme, 2014.
57. Taylor L,. US attacks on New Zealand drug agency draw anger. PharmaTimes Digital, 2011.
58. PHARMAC, Government of New Zealand. High Cost Medicines for Rare Disorders: Discussion document and a request for your input, 2014.
59. PHARMAC, Government of New Zealand. Feedback on draft RFP for medicines for rare disorders, 2014. [Accessed 5 Nov 2014.] Available at: http://www.pharmac.health.nz/news/notification-2014-08-15-rare-disorders/.